Poland· PL-100064072
Streptomycinum TZF
A streptomycin product containing streptomycinum, registered in Poland by Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.. The same ATC class is registered in 7 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Streptomycin is registered in 7 of 19 countries.
Countries holding a registration under ATC J01GA01 (streptomycin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Streptomycin · ATC J01GA01
7 / 19 countries
- Canada
- Czechiaprice
- Finlandprice
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Streptomycinum
- Manufacturer
- Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
- Country
- Poland (PL)
- ATC code
- J01GA01
- ATC class
- Streptomycin
- Defined daily dose
- 1 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909990311415
- gtin05909990311422
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
199 interactions on record for streptomycin.
Graded by severity as the source publishes them — 50 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Streptomycin · interactions on record
199 records
- 50 severe
- 126 moderate
- 2 minor
- 21 info
Most severe, free to view
- Magnesium sulfateA06AD04severe
- MannitolA06AD16severe
- Polymyxin BA07AA05severe
- Magnesium sulfateA12CC02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Streptomycin in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainSULFATO DE ESTREPTOMICINA REIG JOFRE 1 G POLVO PARA SOLUCIÓN INYECTABLELaboratorio Reig Jofre, S.A.
- NorwayStreptomycin x-genPharma-Tek
- United KingdomStreptomycin 1g powder for solution for injection vialsFocus Pharmaceuticals Ltd
- CanadaSTREPTOMYCIN FOR INJECTION USPSTERIMAX INC
- CzechiaSULFATO DE ESTREPTOMICINA REIG JOFRÉ
- United StatesStreptomycinXGen Pharmaceuticals DJB, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Spain · Sulfato De Estreptomicina Reig Jofré
- Portugal · Estreptomicina Labesfal
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/91bbd266-28a0-4ee0-92a7-9e6740719cf6 GET /v1/drugs/91bbd266-28a0-4ee0-92a7-9e6740719cf6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "1 g",
"packaging": "05909990311415 ¦ Rp ¦ 9640\n1 fiol. 1 g proszku\nRp ¦ Skasowane ¦ 9641\n5 fiol. s.subst.\n05909990311422 ¦ Rp ¦ Skasowane ¦ 16017\n20 fiol. s. subst.",
"substance": "Streptomycinum 1000 mg",
"common_name": "Streptomycinum",
"pl_product_id": "100064072",
"pozwolenie_nr": "03114",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about streptomycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.